Novo Nordisk A/S (NYSE:NVO) presented new sub-analyses from its STEP UP clinical trial at the European Congress on Obesity, highlighting that a higher dose of Wegovy helped people with obesity achieve substantial weight loss regardless of how quickly they initially responded to treatment.

The company also said a separate analysis showed most of the weight lost with Wegovy came from body fat, while muscle function was preserved.

• Novo Nordisk stock is trading near recent lows. What’s next for NVO stock?

Higher-Dose Wegovy Delivered Greater Weight Loss

The STEP UP trial evaluated semaglutide 7.2 mg, semaglutide 2.4 mg, and placebo over 72 weeks in more than 1,400 adults with obesity who did not have Type 2 diabetes.

According to the data, participants taking the 7.2 mg dose lost an average of 21% of their body weight, equivalent to roughly 23 kilograms (~ 50 pounds) for the average participant who weighed 113 kilograms before ...